Citations

Showing 10 of 108083 citations.

Effects of Ablation Versus Drug Therapy on Quality of Life by Sex in Atrial Fibrillation: Results From the CABANA Trial
Zeitler, Emily P. , Li, Yanhong , Silverstein, A , Russo, Andrea M. , Poole, Jeanne E. , Daniels, Melanie R. , Al‐Khalidi, Hussein R. , Lee, Kerry L. , Bahnson, Tristram D. , Anstrom, Kevin J. , Packer, Douglas L. , Investigators, for the CABANA, Silverstein, Adam P , Mark, Daniel B , Mark, Daniel B. , Investigators, for the CABANA

Mayo Clinic

Journal of the American Heart Association | January 23, 2023 | Volume: 12 | Issue: 3 | Pages: No page available

10.1161/jaha.122.027871 | PMID 36688367 Get It

Background Women with atrial fibrillation (AF) demonstrate more AF‐related symptoms and worse quality of life (QOL). Whether increased use of ablation in women reduces sex‐related QOL differences is unknown. Sex‐related outcomes for ablation versus drug therapy was a prespecified analysis in the CABANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial. Methods and Results Symptoms were assessed periodically over 60 months with the Mayo AF‐Specific Symptom Inventory (MAFSI) frequency score, and QOL was assessed with the Atrial Fibrillation Effect on Quality of Life (AFEQT) summary and component scores. Women had lower baseline QOL scores than men (mean AFEQT scores 55.9 and 65.6, respectively). Ablation patients improved more than drug therapy patients with similar treatment effect by sex: AFEQT 12‐month mean adjusted treatment difference in women 6.1 points (95% CI, 3.5–8.6) and men 4.9 points (95% CI, 3.0–6.9). Participants with baseline AFEQT summary scores <70 had greater QOL improvement, with a mean treatment difference at 12 months of 7.6 points for women (95% CI, 4.3–10.9) and 6.4 points for men (95% CI, 3.3–9.4). The mean adjusted difference in MAFSI frequency score between women randomized to ablation versus drug therapy at 12 months was −2.5 (95% CI, −3.4 to −1.6); for men, the difference was −1.3 (95% CI, −2.0 to −0.6). Conclusions Compared with drug therapy for AF, ablation resulted in more QOL improvement in both sexes, primarily driven by improvements in those with lower baseline QOL. Ablation did not eliminate the AF‐related QOL gap between women and men. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00911508.
Subclinical Vitamin C Plasma Levels Associated with Increased Risk of CAD Diagnosis via Inflammation: Results from the NHANES 2003–2006 Surveys
Crook, Jennifer , Yoon, Saunjoo L. , Grundmann, Oliver , Johnson‐Mallard, Versie, Crook, Jennifer M, Yoon, Saun-Joo , Horgas, Ann L.

Mayo Clinic

Nutrients | January 23, 2023 | Volume: 15 | Issue: 3 | Pages: 584

10.3390/nu15030584 | PMID 36771290 Get It

Vitamin C remains an important, yet frequently unassessed, component of a healthy immune system though it may prove useful in alleviating the chronic inflammatory processes underlying chronic diseases such as coronary artery disease (CAD). Recent research identified a sizeable proportion of the United States population with insufficient vitamin C plasma levels and significant associations to both acute and chronic inflammation. This cross-sectional study used the 2003–2006 NHANES surveys data to extrapolate associations between plasma vitamin C levels (deficiency, hypovitaminosis, inadequate, adequate, and saturating) and CAD through inflammation (C-reactive protein and red cell distribution width). Increased reports of CAD diagnosis were identified in participants with vitamin C deficiency (OR: 2.31, CI: 1.49–3.58) and inadequate plasma levels (OR: 1.39, CI: 1.03–1.87). No significant correlation was identified between any other plasma vitamin C quintiles and CAD. When inflammation was controlled, previous associations in the deficient level of plasma vitamin C were no longer significant in association with CAD and participants with inadequate plasma vitamin C showed a reduced association to CAD diagnoses (OR: 0.33, CI: 0.13-0.86). Most chronic inflammation and vitamin C plasma statuses do not demonstrate specific signs or symptoms until the deficient level of vitamin C and/or disease. Thus, increased surveillance of both, and healthy nutritional habits remain crucial modifiable risk factors for disease prevention.
The Evolving Landscape of Leptomeningeal Cancer from Solid Tumors: A Systematic Review of Clinical Trials
Marenco-Hillembrand, Lina , Bamimore, Michael , Rosado-Philippi, Julio , Perdikis, Blake , Abarbanel, David N., Quiñones‐Hinojosa, Alfredo , Chaichana, Kaisorn L. , Sherman, Wendy, Bamimore, Michael A

Mayo Clinic

Cancers | January 23, 2023 | Volume: 15 | Issue: 3 | Pages: 685

10.3390/cancers15030685 | PMID 36765643 Get It

Leptomeningeal carcinomatosis (LMC) is a fatal but uncommon complication occurring in 5–15% of patients with stage IV cancer. Current treatment options are ineffective at managing leptomeningeal spread, with a median overall survival (mOS) of 2–6 months. We aimed to conduct a systematic review of the literature to identify past and future therapies for LMC from solid tumors. Forty-three clinical trials (CTs) published between 1982–2022 were identified. Of these, 35 (81.4%) were non-randomized CTs and 8 (18.6%) were randomized CTs. The majority consisted of phase I (16.3%) and phase II CTs (65.1%). Trials enrolled patients with LMC from various primary histology (n = 23, 57.5%), with one CT evaluating LCM from melanoma (2.4%). A total of 21 trials evaluated a single modality treatment. Among CTs, 23.7% closed due to low accrual. Intraventricular (ITV)/intrathecal (IT) drug delivery was the most common route of administration (n = 22, 51.2%) vs. systemic drug delivery (n = 13, 30.3%). Two clinical trials evaluated the use of craniospinal irradiation for LMC with favorable results. LMC continues to carry a dismal prognosis, and over the years, increments in survival have remained stagnant. A paradigm shift towards targeted systemic therapy with continued standardization of efficacy endpoints will help to shed light on promising treatments.
Clear Cell Renal Cell Carcinoma: From Biology to Treatment
Kase, Adam M. , George, Daniel J. , Ramalingam, Sundhar, George, Daniel J.

Mayo Clinic

Cancers | January 23, 2023 | Volume: 15 | Issue: 3 | Pages: 665

10.3390/cancers15030665 | PMID 36765622 Get It

The majority of kidney cancers are detected incidentally and typically diagnosed at a localized stage, however, the development of regional or distant disease occurs in one-third of patients. Over 90% of kidney tumors are renal cell carcinomas, of which, clear cell is the most predominate histologic subtype. Von Hippel Lindau (VHL) gene alterations result in the overexpression of growth factors that are central to the pathogenesis of clear cell carcinoma. The therapeutic strategies have revolved around this tumor suppressor gene and have led to the approval of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor (VEGF) axis. The treatment paradigm shifted with the introduction of immune checkpoint inhibitors (ICI) and programed death-1 (PD-1) inhibition, leading to durable response rates and improved survival. Combinations of TKI and/or ICIs have become the standard of care for advanced clear cell renal cell carcinoma (ccRCC), changing the outlook for patients, with several new and promising therapeutic targets under development.
Outcomes of Surgical Treatment for Extradural Benign Primary Spinal Tumors in Patients Younger than 25 Years: An Ambispective International Multicenter Study
Disch, Alexander C. , Rhines, Laurence D. , Gokaslan, Ziya L., Fisher, Charles G. , Fehlings, Michael G. , Chou, Dean , Germscheid, Nicole M., Schaser, Klaus‐Dieter , Reynolds, Jeremy , Tumor, The AO Spine Knowledge Forum, Reynolds, Jeremy , Rhines, Laurence D , Fehlings, Michael G , Germscheid, Nicole M , Reynolds, Jeremy , Boriani, Stefano , Lazáry, Áron , Luzzati, Alessandro , Clarke, Michelle J. , Tumor, The AO Spine Knowledge Forum

Mayo Clinic

Cancers | January 23, 2023 | Volume: 15 | Issue: 3 | Pages: 650

10.3390/cancers15030650 | PMID 36765605 Get It

Extradural primary spinal tumors were retrospectively analyzed from a prospective database of 1495 cases. All subjects with benign primary tumors under the age of 25 years, who were enrolled between 1990 and 2012 (Median FU was 2.4 years), were identified. Patient- and case-related characteristics were collected and statistically analyzed. Results: 161 patients (66f;95m; age 17.0 ± 4.7 years at time of diagnosis) were identified. The most common tumors were osteoblastomas n = 53 (32.9%), osteoid osteomas n = 45 (28.0%), and aneurysmal bone cysts n = 32 (19.9%). The tumor grade, according to the Enneking Classification S1/S2/S3, was 14/73/74 (8.7/45.3/46.0%), respectively. Tumor-related pain was present in 156 (96.9%) patients. Diagnosis was achieved by biopsies in 2/3 of the cases. Spinal fixation was used in >50% of the cases. Resection was Enneking appropriate in n = 100 (62.1%) of cases. Local recurrence occurred in 21 (13.1%) patients. Two patients died within a 10-year follow-up period. Conclusion: This is one of the largest international multicenter cohorts of young patients surgically treated for benign spinal tumors. The heterogenic young patient cohort presented at a mid-term follow-up without a correlation between the grade of aggressiveness in resection and local recurrence rates. Further prospective data are required to identify prognostic factors that determine oncological and functional outcomes for young patients suffering from these rare tumors.
Changes in CT-Based Morphological Features of the Kidney with Declining Glomerular Filtration Rate in Chronic Kidney Disease
Choi, Yoon Ho , Jo, Seongho , Lee, Ro Woon , Paek, Jin Hyuk , Kim, Byoung Je , Shin, Soo-Yong , Hwang, Seun Deuk , Lee, Seoung Woo, Song, Joon Ho , Kim, Kipyo , Shin, Soo-Yong , Song, Joon Ho , Kim, Jieun , Lee, Seoung Woo

Mayo Clinic

Diagnostics | January 23, 2023 | Volume: 13 | Issue: 3 | Pages: 402

10.3390/diagnostics13030402 | PMID 36766507 Get It

Chronic kidney disease (CKD) progression involves morphological changes in the kidney, such as decreased length and thickness, with associated histopathological alterations. However, the relationship between morphological changes in the kidneys and glomerular filtration rate (GFR) has not been quantitatively and comprehensively evaluated. We evaluated the three-dimensional size and shape of the kidney using computed tomography (CT)-derived features in relation to kidney function. We included 257 patients aged ≥18 years who underwent non-contrast abdominal CT at the Inha University Hospital. The features were quantified using predefined algorithms in the pyRadiomics package after kidney segmentation. All features, except for flatness, significantly correlated with estimated GFR (eGFR). The surface-area-to-volume ratio (SVR) showed the strongest negative correlation (r = −0.75, p < 0.0001). Kidney size features, such as volume and diameter, showed moderate to high positive correlations; other morphological features showed low to moderate correlations. The calculated area under the receiver operating characteristic (ROC) curve (AUC) for different features ranged from 0.51 (for elongation) to 0.86 (for SVR) for different eGFR thresholds. Diabetes patients had weaker correlations between the studied features and eGFR and showed less bumpy surfaces in three-dimensional visualization. We identified alterations in the CKD kidney based on various three-dimensional shape and size features, with their potential diagnostic value.
Urine Output and Mortality in Patients Resuscitated from out of Hospital Cardiac Arrest
Sarma, Dhruv , Jentzer, Jacob C. , Jentzer, Jacob C , Tabi, Meir , Rabinstein, Alejandro A. , Kashani, Kianoush

Mayo Clinic

Journal of Intensive Care Medicine | January 23, 2023 | Volume: 38 | Issue: 6 | Pages: 544-552

10.1177/08850666221151014 | PMID 36683431 Get It

Background Limited data exist regarding urine output (UO) as a prognostic marker in out-of-hospital-cardiac-arrest (OHCA) survivors undergoing targeted temperature management (TTM). Methods We included 247 comatose adult patients who underwent TTM after OHCA between 2007 and 2017, excluding patients with end-stage renal disease. Three groups were defined based on mean hourly UO during the first 24 h: Group 1 (<0.5 mL/kg/h, n = 73), Group 2 (0.5−1 mL/kg/h, n = 81) and Group 3 (>1 mL/kg/h, n = 93). Serum creatinine was used to classify acute kidney injury (AKI). The primary and secondary outcomes respectively were in-hospital mortality and favorable neurological outcome at hospital discharge (modified Rankin Scale [mRS]<3). Results In-hospital mortality decreased incrementally as UO increased (adjusted OR 0.9 per 0.1 mL/kg/h higher; p = 0.002). UO < 0.5 mL/kg/h was strongly associated with higher in-hospital mortality (adjusted OR 4.2 [1.6−10.8], p = 0.003) and less favorable neurological outcomes (adjusted OR 0.4 [0.2−0.8], p = 0.007). Even among patients without AKI, lower UO portended higher mortality (40% vs 15% vs 9% for UO groups 1, 2, and 3 respectively, p < 0.001). Conclusion Higher UO is incrementally associated with lower in-hospital mortality and better neurological outcomes. Oliguria may be a more sensitive early prognostic marker than creatinine-based AKI after OHCA.
The Dynamic and Crucial Role of the Arginine Methylproteome in Myoblast Cell Differentiation
Papanikolaou, Nikolaos A. , Nikolaidis, Marios , Amoutzias, Grigoris D. , Fouza, Ariadni, Papaioannou, Maria , Pandey, Akhilesh , Papavassiliou, Athanasios G. , Amoutzias, Grigorios D , Pandey, Akhilesh

Mayo Clinic

International Journal of Molecular Sciences | January 23, 2023 | Volume: 24 | Issue: 3 | Pages: 2124

10.3390/ijms24032124 | PMID 36768448 Get It

Protein arginine methylation is an extensive and functionally significant post-translational modification. However, little is known about its role in differentiation at the systems level. Using stable isotope labeling by amino acids in cell culture (SILAC) proteomics of whole proteome analysis in proliferating or five-day differentiated mouse C2C12 myoblasts, followed by high-resolution mass spectrometry, biochemical assays, and specific immunoprecipitation of mono- or dimethylated arginine peptides, we identified several protein families that were differentially methylated on arginine. Our study is the first to reveal global changes in the arginine mono- or dimethylation of proteins in proliferating myoblasts and differentiated myocytes and to identify enriched protein domains and novel short linear motifs (SLiMs). Our data may be crucial for dissecting the links between differentiation and cancer growth.
Evaluating temperature gradients across the posterior left atrium with radiofrequency ablation
Sandhu, Amneet , Holman, Blair , Lammers, Steven R. , Cerbin, Lukasz , Barrett, Christopher , Sabzwari, Rafay , Garg, Lohit , Zipse, Matthew M. , Tumolo, Alexis Z. , Alvensleben, Johannes von, West, John J., Varosy, Paul D. , Nguyen, Duy T. , Sauer, William H. , Sauer, William H. , Sauer, William H , Tzou, Wendy , Aleong, Ryan G. , Alvensleben, Johannes C. von , Rosenberg, Michael A. , West, John J. , Tzou, Wendy S.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | January 22, 2023 | Volume: 34 | Issue: 4 | Pages: 880-887

10.1111/jce.15826 | PMID 36682068 Get It

AbstractIntroductionEsophageal injury is a well‐known complication associated with catheter ablation. Though novel methods to mitigate esophageal injury have been developed, few studies have evaluated temperature gradients with catheter ablation across the posterior wall of the left atrium, interstitium, and esophagus.MethodsTo investigate temperature gradients across the tissue, we developed a porcine heart–esophageal model to perform ex vivo catheter ablation on the posterior wall of the left atrium (LA), with juxtaposed interstitial tissue and esophagus. Circulating saline (5 L/min) was used to mimic blood flow along the LA and alteration of ionic content to modulate impedance. Thermistors along the region of interest were used to analyze temperature gradients. Varying time and power, radiofrequency (RF) ablation lesions were applied with an externally irrigated ablation catheter. Ablation strategies were divided into standard approaches (SAs, 10–15 g, 25–35 W, 30 s) or high‐power short duration (HPSD, 10–15 g, 40–50 W, 10 s). Temperature gradients, time to the maximum measured temperature, and the relationship between measured temperature as a function of distance from the site of ablation was analyzed.ResultsIn total, five experiments were conducted each utilizing new porcine posterior LA wall‐esophageal specimens for RF ablation (n = 60 lesions each for SA and HPSD). For both SA and HPSD, maximum temperature rise from baseline was markedly higher at the anterior wall (AW) of the esophagus compared to the esophageal lumen (SA: 4.29°C vs. 0.41°C, p < .0001 and HPSD: 3.13°C vs. 0.28°C, p < .0001). Across ablation strategies, the average temperature rise at the AW of the esophagus was significantly higher with SA relative to HPSD ablation (4.29°C vs. 3.13°C, p = .01). From the start of ablation, the average time to reach a maximum temperature as measured at the AW of the esophagus with SA was 36.49 ± 12.12 s, compared to 16.57 ± 4.54 s with HPSD ablation, p < .0001. Fit to a linear scale, a 0.37°C drop in temperature was seen for every 1 cm increase in distance from the site of ablation and thermistor location at the AW of the esophagus.ConclusionBoth SA and HPSD ablation strategies resulted in markedly higher temperatures measured at the AW of the esophagus compared to the esophageal lumen, raising concern about the value of clinical intraluminal temperature monitoring. The temperature rise at the AW was lower with HPSD. A significant time delay was seen to reach the maximum measured temperature and a modest increase in distance between the site of ablation and thermistor location impacted the accuracy of monitored temperatures.
Never Let Me Go: “Almost Dead” Isn’t Good Enough
Clarke, Michelle J.

Mayo Clinic

The American Journal of Bioethics | January 22, 2023 | Volume: 23 | Issue: 2 | Pages: 60-61

10.1080/15265161.2022.2159586 | PMID 36681921 Get It